Cargando…

Oxidation and Reduction Dual-Responsive Polymeric Prodrug Micelles Co-delivery Precisely Prescribed Paclitaxel and Honokiol for Laryngeal Carcinoma Combination Therapy

Laryngeal carcinoma is the most common head and neck malignancy globally, and chemotherapy is still the most common treatment for this type of carcinoma. Monotherapy has become powerless because of the lack of drugs in the anticancer agent library, the difficult process of new drug discovery, and th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Lanzhu, Wu, Jun, Sun, Zhe, Wang, Wenzhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354237/
https://www.ncbi.nlm.nih.gov/pubmed/35935846
http://dx.doi.org/10.3389/fphar.2022.934632
_version_ 1784763021923450880
author Zhou, Lanzhu
Wu, Jun
Sun, Zhe
Wang, Wenzhong
author_facet Zhou, Lanzhu
Wu, Jun
Sun, Zhe
Wang, Wenzhong
author_sort Zhou, Lanzhu
collection PubMed
description Laryngeal carcinoma is the most common head and neck malignancy globally, and chemotherapy is still the most common treatment for this type of carcinoma. Monotherapy has become powerless because of the lack of drugs in the anticancer agent library, the difficult process of new drug discovery, and the widespread drug resistance. Combination therapy with two agents, in particular Chinese herbal medicines with chemotherapy drugs, is a potential alternative to chemotherapy alone. However, combination therapy faces difficulties in delivering multiple drugs to tumor tissue in a precise ratio. Here, a cocktail polymeric prodrug micelle (PHPPM) was developed using an oxidation and reduction dual-responsive polymeric paclitaxel (PTX) and polymeric honokiol (HK) prodrugs. Both of them were obtained by covalently conjugating the drug to dextran via diselenium bonds. Following optimization and characterization, the PHPPM with the precise mass ratio of PTX and HK was obtained, enabling ratiometric drug loading, synchronized drug release in response to tumor high-level reactive oxygen species and glutathione environment, long blood circulation, and high tumor accumulation. This co-delivery system can effectively inhibit laryngeal carcinoma growth in vitro and in vivo. Codelivery of chemotherapy agents and Chinese herbal medicine with a precise ratio and controlled release of the two drugs at the tumor site provides an effective approach to clinical therapy for other laryngeal carcinomas.
format Online
Article
Text
id pubmed-9354237
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93542372022-08-06 Oxidation and Reduction Dual-Responsive Polymeric Prodrug Micelles Co-delivery Precisely Prescribed Paclitaxel and Honokiol for Laryngeal Carcinoma Combination Therapy Zhou, Lanzhu Wu, Jun Sun, Zhe Wang, Wenzhong Front Pharmacol Pharmacology Laryngeal carcinoma is the most common head and neck malignancy globally, and chemotherapy is still the most common treatment for this type of carcinoma. Monotherapy has become powerless because of the lack of drugs in the anticancer agent library, the difficult process of new drug discovery, and the widespread drug resistance. Combination therapy with two agents, in particular Chinese herbal medicines with chemotherapy drugs, is a potential alternative to chemotherapy alone. However, combination therapy faces difficulties in delivering multiple drugs to tumor tissue in a precise ratio. Here, a cocktail polymeric prodrug micelle (PHPPM) was developed using an oxidation and reduction dual-responsive polymeric paclitaxel (PTX) and polymeric honokiol (HK) prodrugs. Both of them were obtained by covalently conjugating the drug to dextran via diselenium bonds. Following optimization and characterization, the PHPPM with the precise mass ratio of PTX and HK was obtained, enabling ratiometric drug loading, synchronized drug release in response to tumor high-level reactive oxygen species and glutathione environment, long blood circulation, and high tumor accumulation. This co-delivery system can effectively inhibit laryngeal carcinoma growth in vitro and in vivo. Codelivery of chemotherapy agents and Chinese herbal medicine with a precise ratio and controlled release of the two drugs at the tumor site provides an effective approach to clinical therapy for other laryngeal carcinomas. Frontiers Media S.A. 2022-07-22 /pmc/articles/PMC9354237/ /pubmed/35935846 http://dx.doi.org/10.3389/fphar.2022.934632 Text en Copyright © 2022 Zhou, Wu, Sun and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zhou, Lanzhu
Wu, Jun
Sun, Zhe
Wang, Wenzhong
Oxidation and Reduction Dual-Responsive Polymeric Prodrug Micelles Co-delivery Precisely Prescribed Paclitaxel and Honokiol for Laryngeal Carcinoma Combination Therapy
title Oxidation and Reduction Dual-Responsive Polymeric Prodrug Micelles Co-delivery Precisely Prescribed Paclitaxel and Honokiol for Laryngeal Carcinoma Combination Therapy
title_full Oxidation and Reduction Dual-Responsive Polymeric Prodrug Micelles Co-delivery Precisely Prescribed Paclitaxel and Honokiol for Laryngeal Carcinoma Combination Therapy
title_fullStr Oxidation and Reduction Dual-Responsive Polymeric Prodrug Micelles Co-delivery Precisely Prescribed Paclitaxel and Honokiol for Laryngeal Carcinoma Combination Therapy
title_full_unstemmed Oxidation and Reduction Dual-Responsive Polymeric Prodrug Micelles Co-delivery Precisely Prescribed Paclitaxel and Honokiol for Laryngeal Carcinoma Combination Therapy
title_short Oxidation and Reduction Dual-Responsive Polymeric Prodrug Micelles Co-delivery Precisely Prescribed Paclitaxel and Honokiol for Laryngeal Carcinoma Combination Therapy
title_sort oxidation and reduction dual-responsive polymeric prodrug micelles co-delivery precisely prescribed paclitaxel and honokiol for laryngeal carcinoma combination therapy
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354237/
https://www.ncbi.nlm.nih.gov/pubmed/35935846
http://dx.doi.org/10.3389/fphar.2022.934632
work_keys_str_mv AT zhoulanzhu oxidationandreductiondualresponsivepolymericprodrugmicellescodeliverypreciselyprescribedpaclitaxelandhonokiolforlaryngealcarcinomacombinationtherapy
AT wujun oxidationandreductiondualresponsivepolymericprodrugmicellescodeliverypreciselyprescribedpaclitaxelandhonokiolforlaryngealcarcinomacombinationtherapy
AT sunzhe oxidationandreductiondualresponsivepolymericprodrugmicellescodeliverypreciselyprescribedpaclitaxelandhonokiolforlaryngealcarcinomacombinationtherapy
AT wangwenzhong oxidationandreductiondualresponsivepolymericprodrugmicellescodeliverypreciselyprescribedpaclitaxelandhonokiolforlaryngealcarcinomacombinationtherapy